Form 4: Forte Biosciences CEO Paul A. Wagner Reports Stock Transactions

Paul A. Wagner, CEO of Forte Biosciences, reports the acquisition and disposal of common stock and restricted stock units on April 1, 2025.

Summary

• On April 1, 2025, Paul A. Wagner, CEO of Forte Biosciences, reported transactions involving the company's stock.
• Wagner acquired 1,250 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.
• He also disposed of 18 shares of common stock at a price of $7.43.
• Following these transactions, Wagner beneficially owns 79,788 shares of Forte Biosciences common stock.
• The reported transactions also involve restricted stock units, with 1/16th of the RSUs vesting quarterly, beginning February 1, 2023, contingent on continued service.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard SEC filing reporting stock transactions by an executive. There is no inherent positive or negative implication.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for executives of publicly traded companies. It provides transparency to investors regarding the buying and selling of company stock by its leadership.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates

Keywords

Forte Biosciences, Paul A. Wagner, stock transactions, Form 4, restricted stock units, RSU, beneficial ownership, common stock, SEC, insider trading